In this setting, the use of long-acting insulin analogues, when available, is more advisable than the use of classical human Neutral Protamine Hagedorn (NPH) insulin, as they provide less complex and more effective glycemic control with a reduced risk of hypoglycemia [6] and glycemic variability [7]. The gene discussed is INS; the disease is Hypoglycemia.